|0.8409|| -0.0051 / -0.60%|
Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company has a pipeline of therapeutic and aesthetic product development programs based on the first Food and Drug Administration approved cell-based product, LAVIV™ (azficel-T), in aesthetics, all of which are based on the autologous fibroblast cell. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. Fibrocell Science was founded on September 1, 2009 and is headquartered in Exton, PA.
|John M. Maslowski||Chief Executive Officer & Director|
|Michael F. Marino||Secretary, Senior Vice President & General Counsel|
|Kimberly M. Smith||Chief Accounting Officer|